Abstract:Abstract Pancreatic cancer (PCa) can vary between individuals, chemotherapy should ideally be tailored to each patient based on the nature of their disease. The detection of potentially chemo-sensitive tumors would significantly improve response rates and facilitate the selection of effective individualized regimens. Developing a method of assessing the likely effectiveness of anticancer drugs using resected tumors of Blacks and whites before treatment will provide PCa patients with a survival advantage. Therefore, we seek to set up patient derived pancreatic cancer organotypic model to test the drug sensitivities. Four patient-derived primary cancer cells from surgically resected Black (2) and White (2) PCa patients were embedded into 3D matrix containing different concentrations of gelatin matrix (3-9%) and transglutaminase (0.1-1.0mg/ml) to mimic tumor microenvironments. Highly and low/dormant 3D conditions were defined based on the cell proliferation rates determined by CCK-8, MTT, and live/dead assays at day 2, 7, 14 days. Cell morphology, colony formation and matrix remodeling were recorded by live imaging due to the 3D matrix transparent nature. Commonly used pancreatic cancer treatment chemo drugs Gemcitabine (Gem), 5-Flu, Capecitabine together with our newly developed Stearoyl-Gem were tested for drug sensitivities in both 2D culture and 3D organotypic cultures. Cell viability, apoptosis, ROS expression, and ATP level in all treatment conditions were imaged and quantitated. The tumor organotypic model mimic two traits of pancreatic tumor microenvironment, including dense extracellular matrix and high transglutaminase expression. Patient derived cancer cells showed significant differences in cell morphology, proliferation, cluster formation in different stiffness microenvironment. We observed patient specific drug sensitivity in 3D cultures. In general, the drug C50 in 3D was shift to higher concentrations when compared with 2D culture. Spontaneous forming tumoroid further in-sensitize drug treatments if we postponed treatment after cell embedding time extended from 48 hours to 144 hours. The cells exhibited delayed drug responses in 3D when compared post treatment 3-day results to 6-day results. Newly developed Stearoyl-Gem showed higher drug potency when compared with Gem. The established patient-derived primary cancer organotypic model provides a platform for testing therapeutic drugs at tumor cell competent and/or dormant conditions. The high throughput 3D model closely mimics tumor microenvironment and may provide a quick turn-around and cost-effective information for patient treatment. Citation Format: Bo Han, Shuqing Zhao, Edward Agyare, Jose Trvino. Establish patient-derived pancreatic cancer cell organotypic models for personalized drug treatment [abstract]. In: Proceedings of the Twelfth AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2019 Sep 20-23; San Francisco, CA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2020;29(6 Suppl_2):Abstract nr D049.

Abstract 197: Novel 3D bioprinted pancreatic tumor models for anti-cancer drug assessment

Patient-derived 3D Bioprinting Pan-Cancer Drug Screening Platform for Personalized Medicine.

Abstract 651: 3D-bioprinted cancer models for target discovery, drug development, and personalized therapy

A 3D Bio-Printed-Based Model for Pancreatic Ductal Adenocarcinoma

Mimicking tumor microenvironment by 3D bioprinting: 3D cancer modeling

3D Bioprinting Tumor Models Mimic the Tumor Microenvironment for Drug Screening

3D Bioprinting of in Vitro Porous Hepatoma Models: Establishment, Evaluation, and Anticancer Drug Testing

Abstract 5475: Development of high-throughput 3D bioprinted pediatric models for precision medicine

Three-dimensional bio-printing: A new frontier in oncology research

Grafting of 3D Bioprinting to in Vitro Drug Screening: A Review

3D modeling of the exocrine pancreatic unit using tomographic volumetric bioprinting

3D Bioprinting as a Powerful Technique for Recreating the Tumor Microenvironment

Research progress of 3D-bioprinted functional pancreas and in vitro tumor models

Application of a 3D Bioprinted Hepatocellular Carcinoma Cell Model in Antitumor Drug Research.

Bioprinting of patient-derived in vitro intrahepatic cholangiocarcinoma tumor model: establishment, evaluation and anti-cancer drug testing.

Bioprinting of in vitro tumor models for personalized cancer treatment: a review

3D Bioprinted Tumor Model with Extracellular Matrix Enhanced Bioinks for Nanoparticle Evaluation.

Bioprinting of patient-derived<i>in vitro</i>intrahepatic cholangiocarcinoma tumor model: establishment, evaluation and anti-cancer drug testing

Developing Patient-Derived 3D-Bioprinting models of pancreatic cancer

3D bioprinting of an in vitro hepatoma microenvironment model: Establishment, evaluation, and anticancer drug testing

Abstract D049: Establish Patient-Derived Pancreatic Cancer Cell Organotypic Models for Personalized Drug Treatment